Type 1 Diabetes Mellitus Prevention

Overview

Journal Pediatr Endocrinol Diabetes Metab

Publisher Termedia

Specialty Pediatrics

Date 2024 Jan 29

PMID 38282489

Authors

Lidia Groele

Agnieszka Szypowska

Affiliations

Soon will be listed here.

References

Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P . Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986; 2(8499):119-24. DOI: 10.1016/s0140-6736(86)91943-4. View

Fox T, Bewley M, Unrath K, Pedersen M, Anderson R, Jung D . Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res. 2010; 52(3):509-17. PMC: 3035687. DOI: 10.1194/jlr.M010595. View

Moran A, Bundy B, Becker D, DiMeglio L, Gitelman S, Goland R . Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013; 381(9881):1905-15. PMC: 3827771. DOI: 10.1016/S0140-6736(13)60023-9. View

Pescovitz M, Greenbaum C, Bundy B, Becker D, Gitelman S, Goland R . B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2013; 37(2):453-9. PMC: 3898764. DOI: 10.2337/dc13-0626. View

Vatanen T, Franzosa E, Schwager R, Tripathi S, Arthur T, Vehik K . The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018; 562(7728):589-594. PMC: 6296767. DOI: 10.1038/s41586-018-0620-2. View

Siljander H, Honkanen J, Knip M . Microbiome and type 1 diabetes. EBioMedicine. 2019; 46:512-521. PMC: 6710855. DOI: 10.1016/j.ebiom.2019.06.031. View

Groele L, Dzygalo K, Kowalska A, Szypowska A . Prolonged Remission Induced by FENofibrate in children with newly diagnosed type 1 diabetes (PRIFEN): protocol of a randomised controlled trial. BMJ Open. 2024; 14(2):e076882. PMC: 10862295. DOI: 10.1136/bmjopen-2023-076882. View

Frederiksen B, Kroehl M, Fingerlin T, Wong R, Steck A, Rewers M . Association between vitamin D metabolism gene polymorphisms and risk of islet autoimmunity and progression to type 1 diabetes: the diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab. 2013; 98(11):E1845-51. PMC: 3816262. DOI: 10.1210/jc.2013-2256. View

Infante M, Ricordi C, Sanchez J, Clare-Salzler M, Padilla N, Fuenmayor V . Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes. Nutrients. 2019; 11(9). PMC: 6769474. DOI: 10.3390/nu11092185. View

10.

Groele L, Szajewska H, Szalecki M, Swiderska J, Wysocka-Mincewicz M, Ochocinska A . Lack of effect of GG and Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial. BMJ Open Diabetes Res Care. 2021; 9(1). PMC: 8006832. DOI: 10.1136/bmjdrc-2020-001523. View

11.

Jacobsen L, Bundy B, Greco M, Schatz D, Atkinson M, Brusko T . Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technol Ther. 2020; 22(12):948-953. PMC: 7757538. DOI: 10.1089/dia.2020.0305. View

12.

Warshauer J, Bluestone J, Anderson M . New Frontiers in the Treatment of Type 1 Diabetes. Cell Metab. 2019; 31(1):46-61. PMC: 6986815. DOI: 10.1016/j.cmet.2019.11.017. View

13.

Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

14.

Ziegler A, Arnolds S, Kolln A, Achenbach P, Berner R, Bonifacio E . Supplementation with subspecies EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open. 2021; 11(11):e052449. PMC: 8578987. DOI: 10.1136/bmjopen-2021-052449. View

15.

Marek-Trzonkowska N, Mysliwiec M, Iwaszkiewicz-Grzes D, Gliwinski M, Derkowska I, Zalinska M . Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes. J Transl Med. 2016; 14(1):332. PMC: 5131539. DOI: 10.1186/s12967-016-1090-7. View

16.

Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

17.

Primavera M, Giannini C, Chiarelli F . Prediction and Prevention of Type 1 Diabetes. Front Endocrinol (Lausanne). 2020; 11:248. PMC: 7326081. DOI: 10.3389/fendo.2020.00248. View

18.

Ramos E, Dayan C, Chatenoud L, Sumnik Z, Simmons K, Szypowska A . Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023; 389(23):2151-2161. DOI: 10.1056/NEJMoa2308743. View

19.

Moravejolahkami A, Shakibaei M, Fairley A, Sharma M . Probiotics, prebiotics, and synbiotics in type 1 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Diabetes Metab Res Rev. 2023; 40(2):e3655. DOI: 10.1002/dmrr.3655. View

20.

Bock P, Telo G, Ramalho R, Sbaraini M, Leivas G, Martins A . The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2020; 64(1):26-41. DOI: 10.1007/s00125-020-05295-1. View